NeuroOne Receives 180-Day Extension From Nasdaq to Meet Minimum Bid Price Compliance

NeuroOne Medical Technologies received a 180-day extension from Nasdaq to regain compliance with the minimum bid price requirement of $1.00 per share for continued listing on the Nasdaq Capital Market. The extension has no immediate effect on the company's listing status, but the company must regain compliance within the extension period to avoid delisting.